Literature DB >> 19130176

Contemporary issues on clopidogrel therapy.

Giuseppe Patti1, Germano Di Sciascio.   

Abstract

In this paper, data from available studies regarding some contemporary issues on clopidogrel therapy are analyzed. In particular, the following clinical questions have been considered and addressed: (a) Is early clopidogrel treatment needed in patients with acute coronary syndromes treated medically or undergoing percutaneous coronary intervention (PCI)? (b) What is the optimal clopidogrel loading dose in patients undergoing PCI? (c) Is pre-treatment with clopidogrel before PCI needed, or can clopidogrel loading be given in the catheter laboratory before intervention, but after coronary anatomy is known? (d) What is the optimal clopidogrel strategy in patients on chronic clopidogrel therapy undergoing PCI? (e) Does the degree of clopidogrel response influence clinical outcome in patients undergoing PCI?

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19130176     DOI： 10.1007/s11739-008-0220-5

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


  71 in total

1.  Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.

Authors:  Deepak L Bhatt; Michel E Bertrand; Peter B Berger; Philippe L L'Allier; Issam Moussa; Jeffrey W Moses; George Dangas; Megumi Taniuchi; John M Lasala; David R Holmes; Stephen G Ellis; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2002-01-02       Impact factor: 24.094

2.  Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.

Authors:  Giuseppe Patti; Annunziata Nusca; Fabio Mangiacapra; Laura Gatto; Andrea D'Ambrosio; Germano Di Sciascio
Journal:  J Am Coll Cardiol       Date:  2008-09-30       Impact factor: 24.094

3.  Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

Authors:  Thomas Cuisset; Corinne Frere; Jacques Quilici; Pierre-Emmanuel Morange; Lyassine Nait-Saidi; Joseph Carvajal; Agnès Lehmann; Marc Lambert; Jean-Louis Bonnet; Marie-Christine Alessi
Journal:  J Am Coll Cardiol       Date:  2006-09-12       Impact factor: 24.094

4.  Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans.

Authors:  Y Cadroy; J P Bossavy; C Thalamas; L Sagnard; K Sakariassen; B Boneu
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

5.  Stent thrombosis is associated with an impaired response to antiplatelet therapy.

Authors:  Peter Wenaweser; Janine Dörffler-Melly; Katja Imboden; Stephan Windecker; Mario Togni; Bernhard Meier; Andre Haeberli; Otto M Hess
Journal:  J Am Coll Cardiol       Date:  2005-06-07       Impact factor: 24.094

6.  Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort.

Authors:  Tibor Szük; Mariann Gyöngyösi; Nóra Homorodi; Eva Kristóf; Csaba Király; István F Edes; Andrea Facskó; Noemi Pavo; Gottfried Sodeck; Christoph Strehblow; Serdar Farhan; Gerald Maurer; Dietmar Glogar; Hans Domanovits; Kurt Huber; István Edes
Journal:  Am Heart J       Date:  2007-02       Impact factor: 4.749

7.  Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.

Authors:  Wei C Lau; Lucy A Waskell; Paul B Watkins; Charlene J Neer; Kevin Horowitz; Amy S Hopp; Alan R Tait; David G M Carville; Kirk E Guyer; Eric R Bates
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

8.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

Authors:  A Schömig; F J Neumann; A Kastrati; H Schühlen; R Blasini; M Hadamitzky; H Walter; E M Zitzmann-Roth; G Richardt; E Alt; C Schmitt; K Ulm
Journal:  N Engl J Med       Date:  1996-04-25       Impact factor: 91.245

9.  Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.

Authors:  Ashesh N Buch; Suman Singh; Probal Roy; Aamir Javaid; Kimberly A Smith; Christopher E George; Augusto D Pichard; Lowell F Satler; Kenneth M Kent; William O Suddath; Ron Waksman
Journal:  Am J Cardiol       Date:  2007-04-13       Impact factor: 2.778

10.  Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.

Authors:  Sigmund Silber; Per Albertsson; Francisco F Avilés; Paolo G Camici; Antonio Colombo; Christian Hamm; Erik Jørgensen; Jean Marco; Jan-Erik Nordrehaug; Witold Ruzyllo; Philip Urban; Gregg W Stone; William Wijns
Journal:  Eur Heart J       Date:  2005-03-15       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.